Immutep Limited (IMMP), an Australian biotech company developing novel immunotherapy treatments for cancer and autoimmune diseases, announces it participated in two post presentations at ASCO Chicago. TACT-001 (Two ACTive Immunotherapies) A Phase II clinical trial...
Pin It on Pinterest
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site you consent to our use of cookies.Ok
